Relay Therapeutics Jumps 16% on New Clinical Data for Its Lead Drug Outside Cancer
NEW YORK, April 8 —
Relay Therapeutics (RLAY) surged 16% to $13.48 before a single data slide hit the screen. The catalyst: the company announced it will present its first clinical results for lead drug Zovegalisib outside of cancer.
- RLAY shares jumped 16% ahead of initial clinical data on Zovegalisib in vascular anomalies at the ISSVA World Congress 2026
- The company trades at $13.48 with just $15mn in TTM revenue and a negative forward P/E of -8.7x
- The ISSVA presentation will be the first clinical readout for Zovegalisib outside of oncology
What Actually Happened
Relay said it will present initial clinical data on Zovegalisib, a PI3Kα inhibitor, in patients with vascular anomalies at the ISSVA World Congress. The drug has only been tested in cancer until now. Wall Street treated the announcement as a platform validation event: if one molecule works across two unrelated disease areas, the probability-weighted value of the entire pipeline rises.
Vascular anomalies are a group of rare disorders involving abnormal blood vessel growth. PI3Kα drives several subtypes, so the biological rationale is sound. Novartis already sells Alpelisib, a PI3Kα inhibitor, for PIK3CA-related overgrowth spectrum under the brand Vijoice. That drug proved the pathway works. Relay is chasing a validated target, not a novel one.
The Catch
A 16% move on a pre-data announcement is the market writing a check the trial hasn't cashed. There are zero efficacy numbers and zero safety data. This is a stock trading on the promise of a conference poster.
Relay generates $15mn in TTM revenue against what is almost certainly a heavy cash burn, typical of clinical-stage biotech. The negative forward P/E confirms the company is years from profitability. If the ISSVA data disappoints — or shows a safety signal that limits dosing — this 16% gives back fast. Novartis has the head start, the sales force, and the regulatory precedent in this exact pathway.
Bottom Line
The development is worth watching. Showing Zovegalisib works outside oncology would turn Relay from a one-indication pipeline play into a multi-disease platform. That distinction matters when negotiating partnerships or acquisition terms. But at $13.48 on $15mn in revenue, you are buying a story, not a business. The number that matters is the actual response rate in vascular anomalies patients at ISSVA. Everything else is noise until then.
Relay Therapeutics doesn't have a Basis Report yet. Generate a full RLAY analysis here to see how the pipeline stacks up.
Basis Report does not hold positions in securities discussed. This is not investment advice.